Filana Therapeutics Receives Nasdaq Notice for Low Stock Price

What Happened
Filana Therapeutics, Inc. (ticker: FLNA) announced in an 8‑K that on September 17, 2026 it received a written notice from the Nasdaq Stock Market stating the company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price for its common stock has been below $1.00 for the last 30 consecutive business days. The notice does not affect current trading of FLNA shares. Under Nasdaq rules, the company has a 180‑calendar‑day cure period ending March 16, 2027 to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of ten consecutive business days.

Key Details

• Notice date: September 17, 2026.
• Noncompliance reason: closing bid below $1.00 for 30 consecutive business days (violation of Nasdaq Rule 5550(a)(2)).
• Cure period: 180 calendar days (until March 16, 2027); must reach ≥ $1.00 closing price for 10 consecutive business days to regain compliance.
• If not cured, company may qualify for a second 180‑day period; failure to cure or Nasdaq determination could lead to delisting, with the company having the right to appeal. FLNA continues to trade on the Nasdaq Capital Market.

Why It Matters
A Nasdaq deficiency notice signals a risk that the stock could be delisted if the company doesn’t meet the minimum bid requirement. Delisting can reduce liquidity and limit where the stock trades, which may affect investor access and share price. Filana said it will monitor the stock price and “may, if appropriate, consider implementing available options to regain compliance,” but there is no assurance those measures will succeed. Investors should watch the company’s share price and subsequent company updates for progress toward compliance.